Apnimed, Inc. (APMD)

Apnimed, Inc. is a late-stage pharmaceutical company developing oral drug treatments for sleep-related breathing disorders. Its strategy targets the neuromuscular causes of airway collapse during sleep rather than relying on devices such as CPAP machines.

The company's lead candidate, AD109, is a once-nightly pill for obstructive sleep apnea that combines two agents designed to keep upper airway muscles active during sleep. It has been evaluated in Phase 3 clinical trials, and the company is pursuing regulatory approval while exploring additional programs in related conditions.

Apnimed was founded in 2017, is headquartered in Cambridge, Massachusetts, and completed its initial public offering on Nasdaq in 2026.